Model Alzheimer’s disease

Dodart, J. C., Bales, K. R., Gannon, K. S. et al. Immunization reverses memory deficits without reducing brain A(3 burden in Alzheimer s disease model. Nature Neurosci. 5 452M57, 2002. [Pg.790]

Hashimoto M., Hossain S., Shimada T., Sugioka K., Yamasaki H., Fujii Y., Ishibashi Y., Oka J. I., and Shido O. (2002). Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer s disease model rats. J. Neurochem. 81 1084-1091. [Pg.232]

Holtzman DM, Fagan AM, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer s disease model. Ann Neurol 2000 47(6) 739-747. [Pg.124]

N., Armstrong, M., Aerssens, J. Galan-tamine population pharmacokinetics in patients with Alzheimer s disease modeling and simulations. J Clin Pharmacol 2003,43 514-523. [Pg.28]

Chaulran NB, Siegel GJ (2002) Reversal of amyloid beta toxicity in Alzheimer s disease model Tg2576 by intr aventricular antiamyloid beta antibody. J Neurosci Res 69 10-23. [Pg.638]

Dodart JC, Bales BCR, Ganrrorr KS, Greerre S J, DeMattos RB, Mathis C, DeLorrg CA, Wu S, Wu X, Holtzmarr DM, Paul SM (2002) Immurri-zahoir reverses memory deficits without reduchrg brairr Abeta bur-deir hr Alzheimer s disease model. Nat Neurosci 5 452 57. [Pg.638]

Takano M, Yamashita T, Nagano K, Otani M, Maekura K, Kamada H et al (2013) Proteomic analysis of the hippocampus in Alzheimer s disease model mice by using two-dimensional fluorescence difference in gel electrophoresis. Neurosci Lett 534 85-89... [Pg.525]

Zhu Z, Yan J, Jiang W, Yao XG, Chen J, Chen L et al (2013) Arctigenin effectively ameliorates memory impairment in Alzheimer s disease model mice targeting both P-amyloid production and clearance. J Neurosci 33 13138-13149... [Pg.533]

Kim KS, Kim HS, Park JM, Kim HW, Park MK, Lee HS et al (2013) Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer s disease model. Neurobiol Aging 34 2408-2420... [Pg.549]

Corcoran NM, Martin D, Hutter-Paier B et al (2010) Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer s disease model. J Cfin Neturosci 17 1025-1033... [Pg.304]

Guo, Z., Zhang, L., Wu, Z., et al. In Vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer s disease model. Cell Stem Cell 14, 188-202 (2014). doi 10.1016/j.stem.2013.12.001... [Pg.321]

Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, Stephenson D, Gastonguay MR and Corrigan B (2012) Combining patient-level and summary-level data for Alzheimer s disease modeling and simulation a p regression meta-analysis. J Pharmacokinet Pharmacodyn. 39(5) 479-98. [Pg.10]

Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARy-mediated mechanisms in Alzheimer s disease models. PLoS ONE. 6(l) el5, 816. [Pg.194]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...